Literature DB >> 15571507

Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093.

Inês M Araújo1, António Francisco Ambrósio, Ermelindo C Leal, Maria João Verdasca, João Oliveira Malva, Patrício Soares-da-Silva, Arsélio Pato Carvalho, Caetana Monteiro Carvalho.   

Abstract

PURPOSE: Newly designed antiepileptic drugs (AEDs) are being evaluated for their efficacy in preventing seizures and for their toxic profiles. We investigated and compared the toxic effects of two dibenz[b,f]azepine derivatives with anticonvulsant activity, 10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide (BIA2-024) and (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f] azepine-5-carboxamide (BIA2-093), with the structurally related compounds carbamazepine (CBZ) and oxcarbazepine (OXC), both in current use for the treatment of epilepsy.
METHODS: Primary rat hippocampal neurons were used to evaluate neuronal morphology and biochemical changes induced by the AEDs used in this study. Immunocytochemical staining against MAP-2 was used to evaluate neuronal morphology. Reactive oxygen species (ROS) and changes in mitochondrial membrane potential (Psim) were measured by fluorescence techniques. Intracellular adenosine triphosphate (ATP) levels were quantified by high-performance liquid chromatography (HPLC).
RESULTS: Hippocampal neurons treated for 24 h with CBZ or OXC (300 microM) showed degeneration and swelling of neurites, but this effect was not observed in neurons treated with BIA 2-024 or BIA 2-093 (300 microM). ROS production also was increased in neurons treated with OXC, but not in neurons treated with the other AEDs. ATP levels were significantly decreased only in neurons treated with OXC, although the energy charge was not altered. Furthermore, OXC led to a decrease of Psim.
CONCLUSIONS: In all parameters assayed, OXC was more toxic than the other AEDs used. Because the new putative AEDs have previously been shown to have an efficacy in preventing seizures similar to that of CBZ and OXC, and are less toxic to neuronal cells, they may be considered as alternatives to the current available therapies for the treatment of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571507     DOI: 10.1111/j.0013-9580.2004.14104.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  12 in total

Review 1.  Eslicarbazepine acetate (BIA 2-093).

Authors:  Luis Almeida; Patrício Soares-da-Silva
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.

Authors:  Martin E Brown; Rif S El-Mallakh
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

Review 3.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

4.  Cerebellar granule cells cultured from adolescent rats express functional NMDA receptors: an in vitro model for studying the developing cerebellum.

Authors:  R Lisa Popp; Jason C Reneau; Janet S Dertien
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

Review 5.  Pharmacological management of epilepsy: recent advances and future prospects.

Authors:  Cecilie Johannessen Landmark; Svein I Johannessen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro.

Authors:  Martin W Elmlinger; Martin Kriebel; Dan Ziegler
Journal:  Neuromolecular Med       Date:  2011-10-09       Impact factor: 3.843

7.  Risk factors and the outcome of therapy in patients with seizure after Carbamazepine poisoning: A two-year cross-sectional study.

Authors:  Ahmad Yaraghi; Nastaran Eizadi-Mood; Marzieh Salehi; Gholamreza Massoumi; Lejla Zunic; Ali Mohammad Sabzghabaee
Journal:  J Res Pharm Pract       Date:  2015 Jan-Mar

Review 8.  Clinical utility of eslicarbazepine: current evidence.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Massimo Cincotta; Alessia Carelli; Alberto Verrotti
Journal:  Drug Des Devel Ther       Date:  2015-02-10       Impact factor: 4.162

Review 9.  Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy.

Authors:  Renato Tambucci; Claudia Basti; Maria Maresca; Giangennaro Coppola; Alberto Verrotti
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-23       Impact factor: 2.570

10.  A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy.

Authors:  Rajinder P Singh; Jorge J Asconapé
Journal:  J Cent Nerv Syst Dis       Date:  2011-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.